Breaking News, Financial News

Financial Report: Enzon 1Q

Oncaspar sales were up 15% to $14.1 million. DepoCyt sales were $2.5 million (+25%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon 1Q 1Q Revenues: $48.6 million (flat) 1Q Earnings: $6.2 million (earnings were $1.5 million in 1Q08) Comments: Oncaspar sales were up 15% to $14.1 million. DepoCyt sales were $2.5 million (+25%). Abelcet sales were down 16% to $5.9 million. Adagen sales were $7.2 million (+18%). Royalty revenue was $13.6 million (-7%). Contract manufacturing revenue was $5.3 million (-20%)....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters